Search results for " Androgen"

showing 10 items of 75 documents

Intercellular communication and human hepatocellular carcinoma.

2005

We have previously reported that gap junction-mediated intercellular communication (GJIC) can be restored in junctionally deficient human prostate epithelial cells, also suggesting that GJIC activity is regulated by estrogen. In the present work, we report studies on sex steroid regulation of GJIC and proliferative activity in both nontumoral (Chang liver, CL) and malignant (HepG2, Huh7) human liver cells. Junctional activity and liver cell growth were measured using the scrape-loading/dye-transfer (SL/DT) and the MTS assay, respectively. Using the SL/DT, only Huh7 cells exhibited a moderate degree of Junctional activity in basic conditions, while neither CL nor HepG2 cells showed functiona…

Receptors SteroidTime FactorsProliferationCell Communicationchemistry.chemical_compoundNeoplasmsReceptorTumorGeneral NeuroscienceLiver cellLiver NeoplasmsGap JunctionsGap junction-mediated intercellular communication (GJIC)ImmunohistochemistryLiverLiver NeoplasmReceptors AndrogenGap JunctionReceptors ProgesteroneHumanmedicine.medical_specialtyCell signalingCarcinoma HepatocellularTime Factormedicine.drug_classEstroneBiologyGeneral Biochemistry Genetics and Molecular BiologyCell LineHistory and Philosophy of ScienceInternal medicineCell Line TumormedicineCarcinomaEstrogen Receptor betaHumansHepatocellular carcinoma (HCC)SteroidCell ProliferationBiochemistry Genetics and Molecular Biology (all)Cell growthEstrogen Receptor alphamedicine.diseasedigestive system diseasesEndocrinologychemistryEstrogenCell cultureCancer researchNeoplasmAnnals of the New York Academy of Sciences
researchProduct

Molecular topology applied to the discovery of 1-benzyl-2-(3-fluorophenyl)-4-hydroxy-3-(3-phenylpropanoyl)-2H-pyrrole-5-one as a non-ligand-binding-p…

2014

We report the discovery of 1-benzyl-2-(3- fluorophenyl)-4-hydroxy-3-(3-phenylpropanoyl)-2H-pyrrole- 5-one as a novel non-ligand binding pocket (non-LBP) antagonist of the androgen receptor (AR) through the application of molecular topology techniques. This compound, validated through time-resolved fluorescence resonance energy transfer and fluorescence polarization biological assays, provides the basis for lead optimization and structure−activity relationship analysis of a new series of non-LBP AR antagonists. Induced-fit docking and molecular dynamics studies have been performed to establish a consistent hypothesis for the interaction of the new active molecule on the AR surface. Refereed/…

StereochemistryGeneral Chemical EngineeringMolecular ConformationLibrary and Information SciencesMolecular Dynamics Simulationmolecular topologySmall Molecule LibrariesMolecular dynamicschemistry.chemical_compoundStructure-Activity RelationshipUser-Computer Interfaceexperimental validationDrug DiscoveryFluorescence Resonance Energy TransferMoleculeHumansPyrrolesPyrroleBinding SitesChemistryAntagonistAndrogen AntagonistsGeneral Chemistryvirtual screeningComputer Science ApplicationsHigh-Throughput Screening AssaysAndrogen receptorMolecular Docking SimulationFörster resonance energy transferDocking (molecular)Receptors AndrogenThermodynamicsFluorescence anisotropyProtein Binding
researchProduct

The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.

2022

Background Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established. Methods Data from the National Research Council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. Patients were divided in two groups, using a time frame of 90 days. Quality of life was measured through the Italian version of the University of California Los Angeles-Pros…

Waiting timeMalemedicine.medical_specialtyWaiting ListsUrologyLymph node metastasisAndrogen deprivation therapySettore MED/06Prostate cancerPercutaneous Coronary Interventionprostate cancer radical prostatectomy screeningQuality of lifeSettore MED/36Internal medicinemedicineHumansWaiting lists; Prostatic neoplasms; Prostatectomy; Radiotherapy; Androgens; Humans; Male; Prostate; Quality of Life; Waiting Lists; Percutaneous Coronary Intervention; Prostatic NeoplasmsProstatectomySurgical approachRadiotherapybusiness.industryscreeningProstateCancerProstatic NeoplasmsWaiting timeprostate cancermedicine.diseaseradical prostatectomyNephrologyAndrogensQuality of LifeT-stagePositive Surgical Marginbusiness
researchProduct

Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle.

2010

Objectives To investigate the effects of combined hormone replacement therapy (HRT) and its effective agents on the IGF-1 signaling pathway. Design and methods To examine the effects of HRT on skeletal muscle in vivo, we utilized pre- and post-intervention samples from a randomized double blinded trial with 50–57-year-old women. The intervention included the year-long use of either HRT preparation (2 mg 17β-estradiol, E2; 1 mg norethisterone acetate, NETA, n = 10) or placebo (CO, n = 9). Microarray technology and quantitative PCR (qPCR) were used to study the expression of insulin-like growth factor I (IGF-1) and its splice variants as well as IGF-1 receptor, Akt1, mTOR, FOXO1, FOXO3, atrog…

estradioliTranscription GeneticEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalEstrogen receptorpostmenopausal womenMuscle ProteinsFOXO1Receptor IGF Type 10302 clinical medicineEndocrinologyProtein IsoformsTestosteroneInsulin-Like Growth Factor IReceptorRandomized Controlled Trials as Topic0303 health sciencesEstradiolMyogenesisForkhead Box Protein O1TOR Serine-Threonine KinasesEstrogen Replacement TherapyForkhead Box Protein O3Forkhead Transcription FactorsMiddle Agedmedicine.anatomical_structureReceptors EstrogenReceptors AndrogenFemalemedicine.medical_specialtynorethisterone acetate030209 endocrinology & metabolismBiologypostmenopausaalinen nainen03 medical and health sciencesInternal medicinemedicineHumansnoretisteroniasetaattiluurankolihasskeletal muscleMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyhormonikorvaushoitoSKP Cullin F-Box Protein LigasesSkeletal muscleAndrogen receptorNorethindrone AcetateEndocrinologyHormone replacement therapyIGF-1 signalointiNorethindroneIGF-1 signalingProto-Oncogene Proteins c-aktGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct

Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.

2012

Background Hirsutism, defined by the presence of excessive terminal hair in androgen-sensitive areas of the female body, is one of the most common disorders in women during reproductive age. Methods We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, pathophysiology, diagnosis and management of hirsutism. Results The prevalence of hirsutism is ~10% in most populations, with the important exception of Far-East Asian women who present hirsutism less frequently. Although usually caused by relatively benign functional conditions, with the polycystic ovary syndrome leading the list of the most frequent etiologies, hirsutism may be th…

hirsutism; androgen excess; guidelinesmedicine.medical_specialtyPediatricsHirsutismMEDLINETerminal hairAndrogen ExcessSettore MED/13 - EndocrinologiaIntervention (counseling)EpidemiologyMedicineHumansguidelineshirsutismSocieties MedicalHirsutism PCOS Hyperandrogenism Adrenal hyperplasia idiopathic hirsutismGynecologybusiness.industryObstetrics and Gynecologymedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryReproductive Medicinehirsutism androgen excess terminal hair polycystic ovary syndrome guidelinesEtiologyAndrogensFemaleandrogen excessbusinessHair FolliclePolycystic Ovary SyndromeHuman reproduction update
researchProduct

The effects of inositol in the female androgenetic alopecia: preliminary data

2014

inositol androgenetic alopeciaSettore MED/35 - Malattie Cutanee E Veneree
researchProduct

PGK1-AR axis: Benefits of a novel actor in PCOS pathology.

2020

lcsh:R5-920business.industrylcsh:RMEDLINElcsh:MedicineGeneral MedicineBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyPhosphoglycerate KinaseText miningReceptors AndrogenCommentaryMedicineHumansFemaleDisease Susceptibilitybusinesslcsh:Medicine (General)Polycystic Ovary SyndromeSignal TransductionEBioMedicine
researchProduct

Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women

1991

Objective To determine if among hyperandrogenic women acne may be differentiated from hirsutism by markers of peripheral androgen metabolism. Design Prospective outpatient study of 36 hyperandrogenic women and controls divided into groups based on the presence or absence of significant hirsutism and the presence or absence of moderate to severe acne. Serum levels of adrenal and ovarian derived androgens were elevated but similar in all patient groups. Interventions Measurement of serum androgens including metabolites of 5 α -reductase activity: 3 α -androstanediol glucuronide and sulfate and androsterone (A) glucuronide and sulfate. Results 3 α -androstanediol glucuronide and sulfate were e…

medicine.medical_specialtyAndrosteronebusiness.industrymedicine.drug_classHyperandrogenismObstetrics and Gynecologymedicine.diseaseAndrogenchemistry.chemical_compoundEndocrinologyReproductive MedicinechemistryInternal medicineMedicineSerum androgensbusinessGlucuronideAcnehirsutismAndrostanediol glucuronideFertility and Sterility
researchProduct

Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines

2004

Abstract In this study, we tested and compared the endocrine disruption activities of compounds in materials used to package foods (bisphenol A, bisphenol F, and bisphenol A diglycidylether BADGE) with natural molecules (genistein, apigenin, kaempferol, and tangeretin) in the human breast cancer cell lines MCF-7 (ER + ) and MDA-MB453 (AR + ; GR + ). Octylphenol was also chosen as a xenoestrogen reference. Two compounds had no estrogenic activity: BADGE and tangeretin. Genistein was the most active compound in the E-Screen assay with MCF-7, followed by octylphenol, bisphenol F, bisphenol A and apigenin, with kaempferol the least potent. All estrogenic compounds competed with 17β-estradiol fo…

medicine.medical_specialtyBisphenol A[SDV]Life Sciences [q-bio]medicine.medical_treatmentGenisteinAntineoplastic AgentsBreast NeoplasmsEndocrine SystemToxicologySteroid03 medical and health scienceschemistry.chemical_compoundTangeretin0302 clinical medicinePhenolsInternal medicineTumor Cells CulturedmedicineAnticarcinogenic AgentsHumansEstrogens Non-SteroidalApigeninBenzhydryl CompoundsKaempferolsComputingMilieux_MISCELLANEOUS030304 developmental biologyFlavonoids0303 health sciencesDose-Response Relationship DrugFood PackagingGeneral MedicineFlavonesGenistein3. Good health[SDV] Life Sciences [q-bio]XenoestrogenEndocrinologyReceptors EstrogenchemistryMCF-7Receptors Androgen030220 oncology & carcinogenesisApigeninCarcinogensEpoxy CompoundsFemaleKaempferolhormones hormone substitutes and hormone antagonistsFood Science
researchProduct

Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review

2021

Anabolic-androgenic steroids (AASs) are a large group of molecules including endogenously produced androgens, such as testosterone, as well as synthetically manufactured derivatives. AAS use is widespread due to their ability to improve muscle growth for aesthetic purposes and athletes’ performance, minimizing androgenic effects. AAS use is very popular and 1–3% of US inhabitants have been estimated to be AAS users. However, AASs have side effects, involving all organs, tissues and body functions, especially long-term toxicity involving the cardiovascular system and the reproductive system, thereby, their abuse is considered a public health issue. The aim of the proposed review is to highli…

medicine.medical_specialtyLeadership and Managementinjuryorgan damagelcsh:MedicineHealth InformaticsInjuryReviewanabolic androgenic steroidsBioinformaticschronic administration03 medical and health sciences0302 clinical medicineHealth Information ManagementmedicineAASstoxicity.Adverse effect030304 developmental biology0303 health sciencesbiologyToxicitybusiness.industryAthletesHealth PolicyPublic healthlcsh:RtoxicityTestosterone (patch)Organ damageAnabolic-Androgenic Steroidsbiology.organism_classificationAASChronic administrationEducational interventionsWhole bodybusinessLarge groupAnabolic androgenic steroid030217 neurology & neurosurgeryanabolic androgenic steroidHealthcare
researchProduct